vactosertib
Small moleculeexperimental
Clinical trial activity
12 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
10
Phase 3
0
Phase 4
0
Earliest trial started Apr 30, 2019 (NCT03802084)
Timeline
Indications
Studied for
- Carcinoma · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Transitional Cell · Phase 2
- Colorectal Neoplasms · Phase 1
- Dermoid Cyst · Phase 2
- Esophageal Neoplasms · Phase 2
- Hematologic Neoplasms · Phase 1
- Hodgkin Disease · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Melanoma · Phase 2
- Multiple Myeloma · Phase 1
- Myelodysplastic Syndromes · Phase 1
- Myeloproliferative Disorders · Phase 2
- Neoplasms · Phase 1/Phase 2
- Osteosarcoma · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 1
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
- Rectal Neoplasms · Phase 1
- Stomach Neoplasms · Phase 2
Mechanism of action
- Transforming growth factor beta-2INHIBITOR
TGFB2 inhibitor
- TGF-beta receptor type IINHIBITOR
TGF-beta receptor type I inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cccc(-c2[nH]c(CNc3ccccc3F)nc2-c2ccc3ncnn3c2)n1- Mol. weight
- 399.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3260567 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06044311 | Phase 2 | Nov 1, 2023 | Case Western Reserve University |
| NCT05588648 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2023 | MedPacto, Inc. |
| NCT05400122 | Phase 1 | Sep 9, 2022 | Case Western Reserve University |
| NCT05436990 | Phase 2 | Jul 31, 2022 | Yonsei University |
| NCT06219733 | Phase 2 | Nov 23, 2021 | MedPacto, Inc. |
| NCT04893252 | Phase 2 | Jun 1, 2021 | National Cancer Center, Korea |
| NCT04656002 | Phase 2 | Jan 31, 2021 | Sungkyunkwan University |
| NCT04515979 | Phase 2 | Nov 1, 2020 | MedPacto, Inc. |
| NCT04258072 | Phase 1 | Mar 31, 2020 | Sungkyunkwan University |
| NCT04064190 | Phase 2 | Dec 30, 2019 | AstraZeneca, MedPacto, Inc., University of California, San Francisco |
| NCT04103645 | Phase 2 | Sep 30, 2019 | Cornell University |
| NCT03802084 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2019 | Yonsei University |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MedPacto, Inc. | For profit | 4 | 4 | 1 | 2019 |
| Case Western Reserve University | Academic/Hospital | 2 | 2 | 2 | 2022 |
| Sungkyunkwan University | Academic/Hospital | 2 | 2 | 2 | 2020 |
| Yonsei University | Academic/Hospital | 2 | 2 | 1 | 2019 |
| AstraZeneca | For profit | 1 | 0 | 1 | 2019 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| National Cancer Center, Korea | Government | 1 | 1 | 1 | 2021 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2019 |
8 organizations
Page 1 / 1